Miglustat: Treatment of Gaucher's disease ceramide glucosyltransferase inhibitor α-glucosidase inhibitor

Drugs of the Future

Volumn 28, Issue 3, 2003, Pages 229-236

  Sorbera, L A ^a   Castaner J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIVIRUS AGENT; CARBOHYDRATE DERIVATIVE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GLUCOSE; GLUCOSYLTRANSFERASE; GLYCOSPHINGOLIPID; HYDROLASE; IMINOSUGAR; MIGLUSTAT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; BIOSYNTHESIS; BONE MARROW CELL; BRAIN CELL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FLATULENCE; FLU LIKE SYNDROME; GAUCHER DISEASE; HEADACHE; HUMAN; LUNG ALVEOLUS CELL; LYSOSOME; NEUROLOGIC DISEASE; NONHUMAN; SIDE EFFECT; SPLEEN CELL; TREATMENT PLANNING; TREMOR; WEIGHT REDUCTION;

EID: 0038016612     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.03.723080     Document Type: Article

References (60)

1. Matos, C.R.R., Lopes, R.S.C., Lopes, C.C. Synthesis of 1-deoxynojirimycin and N-butyl-1-deoxynojirimycin. Synthesis (Stuttgart) 1999: 571-3.
2. Lopes, C.C., Lopes, R.S.C., Matos, C.R.R. A novelprocess for the synthesis of aza-sugars with biological activity. BR 9902585.
3. Baxter, E.W., Reitz, A.B. Expeditious synthesis of azasugars by the double reductive amination of dicarbonyl sugars. J Org Chem 1994, 59: 3175-85.
4. Reitz, A., Baxter, E. (Ortho-McNeil Pharmaceutical, Inc.). Process for producing polyhydroxylated piperidines and pyrrolidines and cpds. thereof. WO 9205152.
5. Grabner, R.W., Landis, B.H., Wang, P.T., Prunier, M.L., Scaros, M.G. (Pharmacia Corp.). Process for producing N-sub-std.-1-deoxynojirimycin. EP 0477160.
6. Landis, B.H., McLaughlin, J.K., Heeren, R., Grabner, R.W., Wang, P.T. Bioconversion of N-butylglucamine to 6-deoxy-6-butylamino sorbose by Gluconobacter oxydans. Org Process Res Dev 2002, 6: 547-52.
7. Scaros, M.G., Prunier, M.L., Rutter, R.J., Yonan, P.K., Grabner, R., Landis, B. A new and improved synthesis of N-butyl-1-deoxynojirimycin. Chem Ind (New York) 1994, 53: 41-8.
8. Behling, J.R., Farid, P., Khanna, I., Medich, J.R., Prunier, M., Weier, R.M. (Pharmacia Corp.). Process for preparation of 1,5-(alkylimino)-1,5-dideoxy-D-glucitol and derivs. thereof. WO 9117145.
9. Partis, R.A., Koszyk, F.J., Mueller, R.A. (Pharmacia Corp.). Antiviral cpds. US 5310745.
10. Bryant, M.L., Koszyk, F.J., Mueller, R.A., Partis, R.A. (Pharmacia Corp.). Use of 1-deoxynojirimycin and its derivs. for treating mammals infected with respiratory syncytial virus. WO 9522975.
11. Junge, B., Krause, H.P., Müller, L., Puls, W. (Bayer AG). New 3,4,5-trihydroxypiperidine derivs., process for their preparation and medicaments and fodder containing them. DE 2758025, EP 0000947.
12. Walkley, S.U. Cellular pathology of lysosomal storage disorders. Brain Pathol 1998, 8: 175-93.
13. Yamashita, T., Wada, R., Sasaki, T., Deng, C., Bierfreund, U., Sandhoff, K., Proia, R.L. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci USA 1999, 96: 9142-7.
14. Dwek, R.A., Butters, T.D., Platt, F.M., Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 2002, 1: 65-75.
15. Platt, F.M., Jeyakumar, M., Andersson, U. et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001, 24: 275-90.
16. Meikle, P.J., Hopwood, J.J., Clague, A.E., Carey, W.F. Prevalence of lysosomal storage disorders. JAMA - J Am Med Assoc 1999, 281: 249-54.
17. Beutler, E., Grabowski, G. Gaucher disease. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed. C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.), McGraw Hill, New York, 2000, 3635-68.
18. Eng, C., Phelps, R., Kim, L. Enzyme replacement therapy for Fabry disease. J Inherit Metab Dis 2000, 23(Suppl. 1): 222.
19. Van den Hout, J.M., Reuser, A.J., de Klerk, J.B., Arts, W.F., Smeitink, J.A., Van der Ploeg, A.T. Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 2001, 24: 266-74.
20. Erikson, A., Bembi, B., Schiffmann, R. Neuronopathic forms of Gaucher's disease. Baillière's Clin Haematol 1997, 10: 711-23.
21. Krivit, W., Sung, J.H., Shapiro, E.G., Lockman, L.A. Microglia: The effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995, 4: 385-92.
22. Vunnam, R.R., Radin, N.S. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem Phys Lipids 1980, 26: 265-78.
23. Radin, N.S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconjugate J 1996, 13: 153-7.
24. Butters, T.D., Dwek, R.A., Platt, F.M. Inhibition of glycosphingolipid biosynthesis: Application to lysosomal storage disorders. Chem Rev 2000, 100: 4683-96.
25. Butters, T.D., van den Broek, L.A.G.M., Fleet, G.W.J., Krulle, T.M., Wormald, M.R., Dwek, R.A., Platt, F.M. Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron Asymmetry 2000, 11: 113-24.
26. Platt, F.M., Neises, G.R., Dwek, R.A., Butters, T.D. N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994, 269: 8362-5.
27. 3. J Acquir Immune Defic Syndr 1994, 7: 139-47.
28. Platt, F.M., Reinkensmeier, G., Dwek, R.A., Butters, T.D. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem 1997, 272: 19365-72.
29. Platt, F.M., Butters, T.D. Inhibitors of glycosphingolipid biosynthesis. Trends Glycosci Glycotechnol 1995, 7: 495-511.
30. Bieberich, E., Freischutz, B., Suzuki, M., Yu, R.K. Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. J Neurochem 1999, 72: 1040-9.
31. Andersson, U., Butters, T.D., Dwek, R.A., Platt, F.M. N-Butyldeoxygalactonojirimycin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 2000, 59: 821-9.
32. Platt, F.M., Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H., Proia, R.L., Winchester, B., Dwek, R.A., Butters, T.D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 1997, 276: 428-31.
33. Jeyakumar, M., Butters, T.D., Cortina-Borja, M., Hunnam, V., Proia, R.L., Perry, V.H., Dwek, R.A., Platt, F.M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 1999, 96: 6388-93.
34. Cox, T., Lachmann, R., Hollak, C. et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355: 1481-5.
35. Heitner, R., Elstein, D., Aerts, J., Weely, S., Zimran, A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002, 28: 127-33.
36. Zavesca™ hard capsules (miglustat). Summary of product and characteristics. Oxford GlycoSciences Product Fact Sheet November 20, 2002.
37. Zavesca marketing approval sought in Israel. DailyDrugNews.com (Daily Essentials) January 21, 2003.
38. First launch announced for Zavesca. DailyDrugNews.com (Daily Essentials) March 4, 2003.
39. Johnson, V.A., Merrill, D.P., Chou, T.C., Hirsch, M.S. Synergistic inhibition of HIV-1 replication by N-butyl-deoxynojirimycin (N-butyl-DNJ) and zidovudine (AZT). 29th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Houston) 1989, Abst 504.
40. Pottage, J.C., Farrington, K., Spear, G., Benson, C.A., Landay, A., Kessler, H.A. Comparative in vitro anti-HIV activity of four new aminosugar derivatives. 29th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Houston) 1989, Abst 506.
41. Bryant, M., Mueller, R., Smidt, M., Tiemeier, D., Jacobs, G., Platt, F., Butters, T., Karlsson, N., Houseman, K., Marr, J. Anti-HIV properties of α-glucosidase inhibitor SC-48334, the active component of prodrug SC-49483. 9th Int Conf AIDS (June 6-11, Berlin) 1993, Abst WS-A17-6.
42. Fischl, M., Resnick, L., Coombs, R. et al. The preliminary efficacy and safety of N-butyl-deoxynojirimycin (SC-48334), an alpha-glucosidase I inhibitor, in combination with zidovudine (ZDV). 9th Int Conf AIDS (June 6-11, Berlin) 1993, Abst PO-B26-2039.
43. Tierney, M., Pottage, J., Kessler, H., Fischl, M., Richman, D., Merigan, T., Powderly, W., Pettinelli, C., Sherman, J., Hirsch, M. The tolerability and pharmacokinetics of N butyl deoxynojirimycin in patients with advanced HIV disease (ACTG 100). 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 46.
44. Smith, M., Smith, S., Piergies, A., Kowalski, K., Wallemark, C., Sherman, J., Karim, A. Single oral dose safety and pharmacokinetics of SC-49483 (N-butyl deoxynojirimycin [NB-DNJ] pro-drug). 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 715.
45. Ratner, L., Vander Heyden, N. Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs. AIDS Res Hum Retroviruses 1993, 9: 291-7.
46. Block, T.M., Lu, X., Platt, F.M., Foster, G.R., Gerlich, W.H., Blumberg, B.S., Dwek, R.A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 1994, 91: 2235-9.
47. Tierney, M., Pottage, J., Kessler, H. et al. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10: 549-53.
48. Asano, N., Kizu, H., Oseki, K., Tomioka, E., Matsui, K., Okamoto, M., Baba, M. N-Alkylated nitrogen-in-the-ring sugars: Conformational basis of inhibition of glycosidases and HIV-1 replication. J Med Chem 1995, 38: 2349-56.
49. Barranger, J.A. Risks of Gaucher's treatment. Lancet 2000, 356: 1353-4.
50. Mistry, P.K. Treatment of Gaucher's disease with OGT 918. Lancet 2000, 356: 676-7.
51. Ranes, M.K., Manfredi, M.G., El-Abbadi, M.M., Platt, F.M., Seyfried, T.N. N-Butyldeoxynojirimycin reduces growth rate and ganglioside content in mouse barin tumors. Proc Am Assoc Cancer Res 2000, 41: Abst 1640.
52. Jordan, R., Conyers, B., Wang, L. et al. Inhibitors of host ER alpha-glucosidases as potential "resistant proof" therapies for hepatitis C virus infection. Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst H-177.
53. Priestman, D.A., Platt, F.M., Dwek, R.A., Butters, T.D. Imino sugar therapy for type 1 Gaucher disease. Glycobiology 2000, 10: iv-vi.
54. Narita, K., Platt, F.M., Dwek, R.A., Ichikawa, S., Hirabayashi, Y., Butters, T.D. Characterization of imino sugar compounds for inhibition of human ceramide-specific glucosyltransferase. Glycoconjugate J 2000, 17: 92.
55. Lachmann, R.H., Hollak, C.E.M., Aerts, J.M.F.G. et al. Substrate reduction using N-butyldeoxynojirimycin (OGT 918): Clinical trial of a novel oral therapy for Gaucher's disease. J Inherit Metab Dis 2000, 23(Suppl. 1): 217.
56. van Weely, S., Maas, M., Aerts, J. Long-term effects of oral treatment of Gaucher disease with N-butyldeoxynojirimycin (OGT 918) in The Netherlands. Blood 2001, 98(11, Part 1): Abst 955.
57. Zimran, A., Hollak, C., Aerts, J., van Weely, S., Cox, T., Lachmann, R., Hrebicek, M., Elstein, D. Efficacy and tolerability of N-butyldeoxynojirimycin (OGT 918) in adult patients with type 1 Gaucher disease: Long-term follow-up. Blood 2001, 98(11, Part 2): Abst 3695.
58. Heitner, R., Elstein, D., Zimran, A. A dose comparison of the efficacy and safety of oral N-butyldeoxynojirimycin (OGT 918) in clinical studies in Gaucher disease. Blood 2001, 98(11, Part 2): Abst 3704.
59. van der Spoel, A.C., Jeyakumar, M., Butters, T.D., Charlton, H.M., Moore, H.D., Dwek, R.A., Platt, F.M. Reversible infertility in male mice after oral administration of alkylated imino sugars: A nonhormonal approach to male contraception. Proc Natl Acad Sci USA 2002, 99: 17173-8.
60. Ouzounov, S., Mehta, A., Dwek, R.A., Block, T.M., Jordan, R. The combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: Implications for hepatitis C virus (HCV) therapy. Antiviral Res 2002, 55: 425-35.